2017 was a pivotal year for the biomarker, including biomarker-dependent drug approval , center stage for NGS based signatures and breakthroughs in complex disease areas. It is clear the success of an efficacious, patient-centric precision medicine fundamentally rests on a solid predictive biomarker foundation. This importance only heightens as multiple drug developers fight for market share for similar targets in similar indications and healthcare providers and payers demand to see more robust clinical benefit to specific patient cohorts.
Built for biomarker, translational and clinical experts, this portion of the meeting will help you bring novel predictive biomarkers to fruition, overcoming challenges in the heterogeneity of disease, exploratory biomarker endeavours, validation of patient stratifying predictive signatures and a demonstration of clinical utility to accelerate the approval of next generation precision medicines.
Hear data-driven case studies across therapeutic areas and address paradigm shifts in the utilization of multi-marker signatures to ensure you, your team and your wider “precision medicine” function deliver valuable insight into patient selection and treatment decisions and prove the safety, efficacy and value of your targeted therapeutic candidates.
Key topics addressed in 2018: